AngioDynamics, Inc. (ANGO)
USD 8.93
(-3.56%)
USD 8.93
(-3.56%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 252.41 Million USD | 79.93% |
| 2023 | 192.92 Million USD | 4.88% |
| 2022 | 183.94 Million USD | 7.1% |
| 2021 | 171.75 Million USD | 4.53% |
| 2020 | 164.3 Million USD | -0.62% |
| 2019 | 165.33 Million USD | 9.76% |
| 2018 | 150.63 Million USD | -0.21% |
| 2017 | 150.95 Million USD | -5.52% |
| 2016 | 159.77 Million USD | 0.19% |
| 2015 | 159.47 Million USD | 1.34% |
| 2014 | 157.37 Million USD | 7.28% |
| 2013 | 146.69 Million USD | 30.1% |
| 2012 | 112.75 Million USD | 5.82% |
| 2011 | 106.55 Million USD | 0.43% |
| 2010 | 106.09 Million USD | 2.06% |
| 2009 | 103.96 Million USD | 20.39% |
| 2008 | 86.35 Million USD | 11.58% |
| 2007 | 77.39 Million USD | 119.77% |
| 2006 | 35.21 Million USD | 37.29% |
| 2005 | 25.65 Million USD | 24.04% |
| 2004 | 20.67 Million USD | 24.39% |
| 2003 | 16.62 Million USD | 26.24% |
| 2002 | 13.16 Million USD | 823.49% |
| 2001 | 1.42 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 49.79 Million USD | 2.06% |
| 2024 Q3 | 44.17 Million USD | -5.96% |
| 2024 FY | 175.49 Million USD | -9.04% |
| 2024 Q4 | 41.74 Million USD | -5.49% |
| 2024 Q2 | 46.97 Million USD | -5.66% |
| 2023 Q1 | 49.81 Million USD | -1.66% |
| 2023 Q2 | 48.48 Million USD | -2.66% |
| 2023 Q3 | 45.83 Million USD | -5.47% |
| 2023 Q4 | 48.78 Million USD | 6.44% |
| 2023 FY | 192.92 Million USD | 4.88% |
| 2022 FY | 183.94 Million USD | 7.1% |
| 2022 Q4 | 50.65 Million USD | 22.6% |
| 2022 Q3 | 41.31 Million USD | -10.9% |
| 2022 Q2 | 46.37 Million USD | 1.68% |
| 2022 Q1 | 45.6 Million USD | -1.62% |
| 2021 Q4 | 46.35 Million USD | 11.76% |
| 2021 Q3 | 41.47 Million USD | -5.09% |
| 2021 FY | 171.75 Million USD | 4.53% |
| 2021 Q2 | 43.69 Million USD | 8.64% |
| 2021 Q1 | 40.22 Million USD | 4.85% |
| 2020 FY | 164.3 Million USD | -0.62% |
| 2020 Q4 | 38.36 Million USD | -13.89% |
| 2020 Q3 | 44.55 Million USD | 2.65% |
| 2020 Q2 | 43.4 Million USD | 14.23% |
| 2020 Q1 | 37.99 Million USD | -11.09% |
| 2019 Q2 | 42.15 Million USD | 6.17% |
| 2019 FY | 165.33 Million USD | 9.76% |
| 2019 Q1 | 39.7 Million USD | 0.52% |
| 2019 Q4 | 42.73 Million USD | 4.87% |
| 2019 Q3 | 40.74 Million USD | -3.35% |
| 2018 Q2 | 36.76 Million USD | -3.25% |
| 2018 Q1 | 37.99 Million USD | -0.17% |
| 2018 FY | 150.63 Million USD | -0.21% |
| 2018 Q4 | 39.5 Million USD | 8.58% |
| 2018 Q3 | 36.38 Million USD | -1.03% |
| 2017 FY | 150.95 Million USD | -5.52% |
| 2017 Q2 | 37.51 Million USD | -2.82% |
| 2017 Q3 | 36.78 Million USD | -1.95% |
| 2017 Q4 | 38.06 Million USD | 3.48% |
| 2017 Q1 | 38.6 Million USD | -3.01% |
| 2016 Q3 | 37.78 Million USD | -6.23% |
| 2016 Q1 | 39.6 Million USD | -3.24% |
| 2016 FY | 159.77 Million USD | 0.19% |
| 2016 Q2 | 40.29 Million USD | 1.75% |
| 2016 Q4 | 39.79 Million USD | 5.32% |
| 2015 FY | 159.47 Million USD | 1.34% |
| 2015 Q1 | 39.13 Million USD | -2.07% |
| 2015 Q4 | 40.93 Million USD | 4.24% |
| 2015 Q3 | 39.26 Million USD | -2.23% |
| 2015 Q2 | 40.16 Million USD | 2.64% |
| 2014 Q3 | 39.2 Million USD | -1.34% |
| 2014 Q1 | 38.46 Million USD | -0.32% |
| 2014 Q4 | 39.95 Million USD | 1.92% |
| 2014 Q2 | 39.73 Million USD | 3.32% |
| 2014 FY | 157.37 Million USD | 7.28% |
| 2013 Q1 | 36.25 Million USD | 24.06% |
| 2013 FY | 146.69 Million USD | 30.1% |
| 2013 Q4 | 38.58 Million USD | 9.13% |
| 2013 Q3 | 35.35 Million USD | -3.67% |
| 2013 Q2 | 36.7 Million USD | 1.24% |
| 2012 Q1 | 28.5 Million USD | 1.16% |
| 2012 FY | 112.75 Million USD | 5.82% |
| 2012 Q4 | 29.22 Million USD | 7.71% |
| 2012 Q3 | 27.13 Million USD | -2.75% |
| 2012 Q2 | 27.89 Million USD | -2.14% |
| 2011 Q2 | 25.36 Million USD | -4.42% |
| 2011 FY | 106.55 Million USD | 0.43% |
| 2011 Q4 | 28.17 Million USD | 6.44% |
| 2011 Q1 | 26.53 Million USD | -7.12% |
| 2011 Q3 | 26.47 Million USD | 4.36% |
| 2010 Q4 | 28.57 Million USD | 15.78% |
| 2010 FY | 106.09 Million USD | 2.06% |
| 2010 Q3 | 24.68 Million USD | -6.11% |
| 2010 Q1 | 26.55 Million USD | -4.92% |
| 2010 Q2 | 26.28 Million USD | -1.02% |
| 2009 FY | 103.96 Million USD | 20.39% |
| 2009 Q1 | 23.63 Million USD | -18.48% |
| 2009 Q4 | 27.93 Million USD | 1.23% |
| 2009 Q3 | 27.59 Million USD | 11.24% |
| 2009 Q2 | 24.8 Million USD | 4.94% |
| 2008 Q2 | 20.66 Million USD | 8.88% |
| 2008 FY | 86.35 Million USD | 11.58% |
| 2008 Q3 | 17.71 Million USD | -14.28% |
| 2008 Q1 | 18.98 Million USD | -5.18% |
| 2008 Q4 | 28.99 Million USD | 63.66% |
| 2007 Q3 | 36.03 Million USD | 220.58% |
| 2007 FY | 77.39 Million USD | 119.77% |
| 2007 Q2 | 11.24 Million USD | 11.25% |
| 2007 Q4 | 20.01 Million USD | -44.45% |
| 2007 Q1 | 10.1 Million USD | -3.81% |
| 2006 Q2 | 8.44 Million USD | 11.06% |
| 2006 Q4 | 10.5 Million USD | 21.3% |
| 2006 Q3 | 8.65 Million USD | 2.51% |
| 2006 Q1 | 7.6 Million USD | 5.07% |
| 2006 FY | 35.21 Million USD | 37.29% |
| 2005 Q4 | 7.23 Million USD | 12.81% |
| 2005 FY | 25.65 Million USD | 24.04% |
| 2005 Q3 | 6.41 Million USD | 2.33% |
| 2005 Q1 | 5.72 Million USD | 2.12% |
| 2005 Q2 | 6.27 Million USD | 9.58% |
| 2004 Q3 | 5.02 Million USD | 0.0% |
| 2004 Q4 | 5.6 Million USD | 11.52% |
| 2004 FY | 20.67 Million USD | 24.39% |
| 2003 FY | 16.62 Million USD | 26.24% |
| 2003 Q4 | 14.85 Million USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2002 FY | 13.16 Million USD | 823.49% |
| 2001 FY | 1.42 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 104.27 Million USD | -142.079% |
| AtriCure, Inc. | 327.05 Million USD | 22.821% |
| Avinger, Inc. | 18.63 Million USD | -1254.308% |
| Azenta, Inc. | 336.26 Million USD | 24.936% |
| BioLife Solutions, Inc. | 117.57 Million USD | -114.681% |
| The Cooper Companies, Inc. | 1.82 Billion USD | 86.167% |
| Daxor Corporation | 1.28 Million USD | -19612.069% |
| Ekso Bionics Holdings, Inc. | 24.19 Million USD | -943.429% |
| Femasys Inc. | 15.2 Million USD | -1560.597% |
| GlucoTrack, Inc. | 7.1 Million USD | -3453.153% |
| Harvard Bioscience, Inc. | 58.58 Million USD | -330.884% |
| Hologic, Inc. | 1.34 Billion USD | 81.236% |
| ICU Medical, Inc. | 717.04 Million USD | 64.798% |
| Intuitive Surgical, Inc. | 2.96 Billion USD | 91.48% |
| KORU Medical Systems, Inc. | 26.1 Million USD | -866.82% |
| LeMaitre Vascular, Inc. | 90.33 Million USD | -179.416% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 211629.469% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 211629.469% |
| Masimo Corporation | 867 Million USD | 70.886% |
| Microbot Medical Inc. | 9.85 Million USD | -2461.299% |
| Meihua International Medical Technologies Co., Ltd. | 18.42 Million USD | -1270.332% |
| Merit Medical Systems, Inc. | 459.92 Million USD | 45.118% |
| Nephros, Inc. | 9.78 Million USD | -2479.886% |
| NovoCure Limited | 613.92 Million USD | 58.885% |
| NEXGEL, Inc. | 4.09 Million USD | -6062.5% |
| NEXGEL, Inc. | 4.09 Million USD | -6062.5% |
| Singular Genomics Systems, Inc. | 102.24 Million USD | -146.879% |
| OraSure Technologies, Inc. | 125.34 Million USD | -101.382% |
| Pro-Dex, Inc. | 7.37 Million USD | -3321.198% |
| Pulse Biosciences, Inc. | 43.57 Million USD | -479.281% |
| Predictive Oncology Inc. | 15.22 Million USD | -1557.412% |
| Precision Optics Corporation, Inc. | 8.52 Million USD | -2861.896% |
| QuidelOrtho Corporation | 1.35 Billion USD | 81.376% |
| Repligen Corporation | 261.12 Million USD | 3.334% |
| Sanara MedTech Inc. | 61.12 Million USD | -312.936% |
| STAAR Surgical Company | 224.55 Million USD | -12.408% |
| Sharps Technology, Inc. | 10.12 Million USD | -2392.591% |
| Utah Medical Products, Inc. | 13.26 Million USD | -1803.446% |
| DENTSPLY SIRONA Inc. | 1.79 Billion USD | 85.93% |
| Jin Medical International Ltd. | 3.91 Million USD | -6343.174% |